Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130331) titled 'Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis' on Aug. 12.
Study Type: Observational
Primary Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Condition:
Axial Spondylarthritis (axSpA)
Secukinumab
Intervention:
Drug: Secikinumab
Recruitment Status: Not recruiting
Date of First Enrollment: June 1, 2020
Target Sample Size: 200
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07130331
Published by HT Digital Content Services with permission from Health Daily Digest....